NEJM at ESC — Beta Blocker Interruption or Continuation with Prior Myocardial Infarction
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual...
Beta-Blocker Interruption or Continuation after Myocardial Infarction
Among patients with a previous myocardial infarction, interruption of long-term beta-blocker therapy was not found to be noninferior to continuation with respect to adverse...
Routine Beta-Blockers in Secondary Prevention — Approaching Retirement?
Nearly half a century ago, trials were performed that provided convincing evidence that long-term treatment with beta-blockers can improve outcomes after a myocardial infarction.1-3...
NEJM at ESC — Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual...
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Among patients with transthyretin amyloidosis with cardiomyopathy, the risk of death from any cause and recurrent cardiovascular events was lower with vutrisiran treatment than...
